Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$28 Mln
P/E Ratio
--
P/B Ratio
1.43
Industry P/E
--
Debt to Equity
0.8
ROE
-1.82 %
ROCE
-102.16 %
Div. Yield
0 %
Book Value
9.56
EPS
-20.92
CFO
$-356.43 Mln
EBITDA
$-429.85 Mln
Net Profit
$-442.67 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
| -25.37 | -25.86 | -33.74 | -82.41 | -41.24 | -51.70 | -60.28 |
|
BSE Sensex
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
| -80.78 | 282.61 | -78.22 | -83.55 | -68.25 | -15.22 | -61.94 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.18 | 10,315.11 | 21.27 | 23.13 | |
| 300.25 | 8,705.27 | 22.77 | 66.44 | |
| 27.51 | 10,589.59 | -- | -28.77 | |
| 106.77 | 10,559.67 | 32.44 | 14.16 |
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers. The company's two clinical programs Amezalpat formerly... PST-1120, an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha, which is in Phase III; and TPST-1495, a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, which is in Phase II. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. Read more
CEO, President & Director
Mr. Stephen R. Brady J.D., LLM
CEO, President & Director
Mr. Stephen R. Brady J.D., LLM
Headquarters
Brisbane, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tempest Therapeutics Inc (TPST) stood at $ 41 Mln as on 31-Dec-24
The share price of Tempest Therapeutics Inc (TPST) is $8.10 (NASDAQ) as of 28-Apr-2025 10:39 EDT. Tempest Therapeutics Inc (TPST) has given a return of -41.24% in the last 3 years.
Tempest Therapeutics Inc (TPST) has a market capitalisation of $ 28 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tempest Therapeutics Inc (TPST) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tempest Therapeutics Inc (TPST) and enter the required number of quantities and click on buy to purchase the shares of Tempest Therapeutics Inc (TPST).
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers. The company's two clinical programs Amezalpat formerly PST-1120, an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha, which is in Phase III; and TPST-1495, a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, which is in Phase II. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
The CEO & director of Mr. Stephen R. Brady J.D., LLM. is Tempest Therapeutics Inc (TPST), and CFO & Sr. VP is Mr. Stephen R. Brady J.D., LLM.
There is no promoter pledging in Tempest Therapeutics Inc (TPST).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Tempest Therapeutics Inc. (TPST) | Ratios |
|---|---|
|
Return on equity(%)
|
-182.35
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tempest Therapeutics Inc (TPST) was $0 Mln.
$0.34
(
